{
  "id": 10513645,
  "title": "Mirum reports Phase 3 victory for acquired hepatitis D med",
  "url": "https://urgent.news/2026/09/28/mirum-reports-phase-3-victory-for-acquired-hepatitis-d-med",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T18:50:33.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/mirum-reports-phase-3-victory-for-acquired-hepatitis-d-med/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Mirum Pharmaceuticals’ recently purchased chronic hepatitis delta treatment has scored a Phase 3 win, adding momentum behind the company’s pipeline and commercial future. More than half of patients who received a once-weekly 300 mg shot ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Mirum to present phase 3 hepatitis delta study results Monday",
        "url": "https://urgent.news/2026/09/27/mirum-to-present-phase-3-hepatitis-delta-study-results-monday",
        "published": "2026-09-27T21:04:30.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "Mirum falls despite meeting primary goal in phase 3 brelovitug study for hepatitis D",
        "url": "https://urgent.news/2026/09/28/mirum-falls-despite-meeting-primary-goal-in-phase-3-brelovitug-study",
        "published": "2026-09-28T15:44:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}